IQVIA Holdings Inc. ("IQVIA") , a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2024..
Revenue of $4.8 billion declined 1.1% year-over-year, or declined 1.2% in constant currency1, which was above the high-end of our guidance range.
Operating margin of 14.6%, flat year-over-year, and.
First quarter consolidated revenue declined 10% on lower industry demand First quarter diluted EPS at $0.31; adjusted diluted EPS at $0.33 First quarter Agriculture segment adjusted EBIT margin.
REO production of 11,151 metric tons, the second highest ever
Initial design capacity of magnetics facility fully committed
Repurchased 13.0 million shares of common stock, or 7.3% of shares.